New combo therapy targets tough lymphoma
Disease control
Recruiting now
This study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that has returned or not responded to prior treatment. About 24 participants will receive…
Phase: PHASE2 • Sponsor: Aseel Alsouqi • Aim: Disease control
Last updated May 17, 2026 12:01 UTC